Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults

NCT05889845 is registered in ClinicalTrials.gov with Nielsen BioSciences, Inc. as lead sponsor.

NCT NCT05889845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05889845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults
Lead sponsor
Nielsen BioSciences, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 22, 2025
Completion date
August 27, 2025
Enrollment
330 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

common warts (verruca vulgaris)